The game is now open in the massive Chinese market. These customer contracts could start coming in at a steady pace. Wiser Asia is a great partner in this.
Based on what I’ve read, health sector operators in China rely heavily on pilots conducted by leading institutions. In other words, they adopt the product without a major pilot of their own. Large players likely conduct smaller-scale pilots that are not lengthy in duration.
Waiting for new China contracts… and they will certainly come.
The India launch is next in line. I’m expecting this to happen soon as well.
Big Pharma… this too, of course.